CAL
EDIT icon

Capital Analysts LLC’s Editas Medicine EDIT Stock Holding History

Capital Analysts LLC’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-43
Closed -$1K – 1017
2022
Q1 		$1K Hold
43
– – ﹤0.01% 893
2021
Q4 		$1K Hold
43
– – ﹤0.01% 974
2021
Q3 		$2K Buy
+43
New +$2.36K ﹤0.01% 926

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Capital Analysts LLC's EDIT Position: Q2 2022 in Review

Capital Analysts LLC sold out of Editas Medicine (EDIT) in Q2 2022, closing a stake of 43 shares — an estimated $1K sold.

Capital Analysts LLC first reported a position in EDIT in Q3 2021 and held it in 3 quarters. The position peaked at $2K in Q3 2021. 256 funds tracked by Wall St. Rank hold EDIT as of Q2 2022.

  • Capital Analysts LLC reported no remaining Editas Medicine position as of Q2 2022 after selling out during the quarter.
  • Capital Analysts LLC sold 43 Editas Medicine shares in Q2 2022, an estimated $1K.
  • Capital Analysts LLC first reported a position in Editas Medicine in Q3 2021 and held it in 3 quarters.
  • Capital Analysts LLC's Editas Medicine position peaked at $2K in Q3 2021.
  • 256 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2022.

Based on Capital Analysts LLC's 13F filing for Q2 2022, filed 12 Aug 2022.